Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Abstract Background Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and diseas...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2023-08-01
|
| Serier: | Experimental Hematology & Oncology |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s40164-023-00434-x |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
